Foghorn Therapeutics Inc. (FHTX)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Adrian Gottschalk
Employees:
120
500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE, MA 02139
617-586-3100

Foghorn Therapeutics Inc. is developing a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome. The company is also developing an enzyme inhibitor and protein degrader as selective modulators of BRM.

Data derived from most recent annual or quarterly report
Market Cap 182.1 Million Shares Outstanding41.862 Million Avg 30-day Volume 103.394 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.34
Price to Revenue6.4516 Debt to Equity0.0 EBITDA-110.84 Million
Price to Book Value0.0 Operating Margin-351.0408 Enterprise Value-49.758 Million
Current Ratio5.104 EPS Growth0.089 Quick Ratio4.997
1 Yr BETA 1.3238 52-week High/Low 9.97 / 2.84 Profit Margin-316.8744
Operating Cash Flow Growth-150.9726 Free Cash Flow to Firm (FCFF) TTM -111.958 Million Free Cash Flow to Equity (FCFE) TTM
Altman Z-Score-1.9122
View SEC Filings from FHTX instead.

View recent insider trading info

Foghorn Therapeutics Inc. YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding FHTX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding FHTX

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-08-18 by GOTTSCHALK ADRIAN
  • 4: filed on 2023-05-31 by GOTTSCHALK ADRIAN
  • 4: filed on 2023-02-22 by GOTTSCHALK ADRIAN
  • 4: filed on 2023-01-30 by COSTA CARLOS
  • 4: filed on 2023-01-30 by LACASCIA MICHAEL
  • 4: filed on 2023-01-30 by GOTTSCHALK ADRIAN
  • 4: filed on 2022-10-31 by LYNCH THOMAS J. JR.
  • 3: filed on 2022-10-31 by LYNCH THOMAS J. JR.
  • 4: filed on 2022-09-19 by GOTTSCHALK ADRIAN
  • 3/A: filed on 2022-09-13 by SMITH IAN F

    • Events (8k)

  • 8-K: filed on 2023-11-02:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-09-08:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-31:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-10:
    Item 1.02: Termination of a Material Definitive Agreement
  • 8-K: filed on 2023-08-08:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-28:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-22:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2023-06-05:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

  • 144: filed on 2023-08-16:

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    AGRESTA SAMUEL CHIEF MEDICAL OFFICER

    • Officer
    		 0 2023-09-11 3

    CARDAMA ALFONSO QUINTAS CHIEF MEDICAL OFFICER

    • Officer
    		 0 2023-09-11 2

    GOTTSCHALK ADRIAN CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 511,704 2023-08-17 3

    PARSHALL B LYNNE

    • Director
    		 0 2023-06-21 1

    GILL SIMBA

    • Director
    		 0 2023-06-21 1

    SMITH IAN F

    • Director
    		 0 2023-06-21 1

    LYNCH THOMAS J. JR.

    • Director
    		 0 2023-06-21 1

    COLE DOUGLAS G.

    • Director
    		 0 2023-06-21 1

    KOPPEL ADAM

    • Director
    		 0 2023-06-21 1

    BILLER SCOTT

    • Director
    		 0 2023-06-21 1

    MENDELSOHN MICHAEL

    • Director
    		 0 2023-06-21 1

    REINE ALLAN CHIEF FINANCIAL OFFICER

    • Officer
    		 90,000 2023-01-26 1

    BELLON STEVEN F. CHIEF SCIENTIFIC OFFICER

    • Officer
    		 100,000 2023-01-26 1

    LACASCIA MICHAEL CHIEF LEGAL OFFICER

    • Officer
    		 90,000 2023-01-26 1

    CAVALIE FANNY CHIEF STRATEGY/BUS OPS OFFICER

    • Officer
    		 65,000 2023-01-26 1

    COSTA CARLOS CHIEF PEOPLE OFFICER

    • Officer
    		 65,000 2023-01-26 1

    KADOCH CIGALL

    • Director
    		 3,624,379 2022-08-31 0

    DILLON ADRIAN T

    • Director
    		 0 2022-06-23 0

    WELLER TIMOTHY CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 0 2022-06-23 0

    SEVERANCE WILLIAM CHIEF ACCOUNTING OFFICER

    • Officer
    		 0 2022-06-23 0

    ABBOT JOHN CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2022-06-23 0

    LARSEN CHRISTINE E

    • Director
    		 0 2022-06-23 0

    BROWN MARC EVAN

    • Director
    		 0 2022-06-23 0

    MCCLOSKEY CHRISTOPHER EDWARD CHIEF CUSTOMER OFFICER

    • Officer
    		 0 2022-06-23 0

    MENON RADHESH BALAKRISHNAN CHIEF PRODUCT OFFICER

    • Officer
    		 0 2022-06-23 0

    SINGH SANJAY KUMAR CHIEF REVENUE OFFICER

    • Officer
    		 0 2022-06-23 0

    PETROCELLI ROBERT RAYMOND CHIEF TECHNOLOGY OFFICER

    • Officer
    		 0 2022-06-23 0

    EPSTEIN EMILY T GENERAL COUNSEL

    • Officer
    		 0 2022-06-23 0

    DECICCO CARL CHIEF SCIENTIFIC OFFICER

    • Officer
    		 583,551 2021-12-09 0

    DILLON JACK K

    • Director
    		 0 2021-10-19 0

    FLAGSHIP VENTURES FUND V GENERAL PARTNER LLC

    FLAGSHIP VENTURES OPPORTUNITIES FUND I GENERAL PARTNER LLC

    FLAGSHIP PIONEERING SPECIAL OPPORTUNITIES FUND II GENERAL PARTNER LLC

    FLAGSHIP VENTURES FUND V, L.P.

    FLAGSHIP VENTURES OPPORTUNITIES FUND I, L.P.

    FLAGSHIP PIONEERING SPECIAL OPPORTUNITIES FUND II, L.P.

    FLAGSHIP PIONEERING INC.

    AFEYAN NOUBAR

    • 10% Owner
    		 12,674,120 2020-10-27 0

    ABU DHABI INVESTMENT AUTHORITY

    PLATINUM INTERNATIONAL INVESTMENT HOLDING RSC LTD

    PLATINUM FALCON B 2018 RSC LTD

    • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
    		 1,231,081 2020-10-27 0

    BASELGA JOSE

    • Director
    		 94,594 2020-10-22 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    FOGHORN THERAPEUTICS INC FHTX 2023-11-28 22:15:04 UTC 4.1863 1.1337 150000
    FOGHORN THERAPEUTICS INC FHTX 2023-11-28 21:45:03 UTC 4.1863 1.1337 150000
    FOGHORN THERAPEUTICS INC FHTX 2023-11-28 21:15:04 UTC 4.1863 1.1337 150000
    FOGHORN THERAPEUTICS INC FHTX 2023-11-28 20:45:04 UTC 4.1863 1.1337 150000
    FOGHORN THERAPEUTICS INC FHTX 2023-11-28 20:15:04 UTC 4.1863 1.1337 150000
    FOGHORN THERAPEUTICS INC FHTX 2023-11-28 19:45:03 UTC 4.1863 1.1337 150000
    FOGHORN THERAPEUTICS INC FHTX 2023-11-28 19:15:04 UTC 4.1863 1.1337 150000
    FOGHORN THERAPEUTICS INC FHTX 2023-11-28 18:45:03 UTC 4.1863 1.1337 150000
    FOGHORN THERAPEUTICS INC FHTX 2023-11-28 18:15:03 UTC 4.1863 1.1337 150000
    FOGHORN THERAPEUTICS INC FHTX 2023-11-28 17:45:04 UTC 4.1863 1.1337 150000
    FOGHORN THERAPEUTICS INC FHTX 2023-11-28 17:15:04 UTC 4.1863 1.1337 150000
    FOGHORN THERAPEUTICS INC FHTX 2023-11-28 16:45:04 UTC 4.1863 1.1337 150000
    FOGHORN THERAPEUTICS INC FHTX 2023-11-28 16:15:04 UTC 4.1863 1.1337 150000
    FOGHORN THERAPEUTICS INC FHTX 2023-11-28 15:45:03 UTC 4.1863 1.1337 150000
    FOGHORN THERAPEUTICS INC FHTX 2023-11-28 15:15:03 UTC 4.1863 1.1337 150000
    FOGHORN THERAPEUTICS INC FHTX 2023-11-28 14:45:04 UTC 4.1863 1.1337 20000
    FOGHORN THERAPEUTICS INC FHTX 2023-11-28 14:15:04 UTC 4.1863 1.1337 20000
    FOGHORN THERAPEUTICS INC FHTX 2023-11-28 13:45:04 UTC 4.1207 1.1993 20000
    FOGHORN THERAPEUTICS INC FHTX 2023-11-28 13:15:03 UTC 4.1207 1.1993 20000
    FOGHORN THERAPEUTICS INC FHTX 2023-11-28 12:45:04 UTC 4.1207 1.1993 20000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund FHTX -800.0 shares, $-4000.0 2023-09-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments